These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28557577)

  • 1. The next chapter for group B meningococcal vaccines.
    Wang NY; Pollard AJ
    Crit Rev Microbiol; 2018 Feb; 44(1):95-111. PubMed ID: 28557577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling serogroup B invasive meningococcal disease: the Canadian perspective.
    Bettinger JA; Deeks SL; Halperin SA; Tsang R; Scheifele DW
    Expert Rev Vaccines; 2013 May; 12(5):505-17. PubMed ID: 23659299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neisseria meningitidis B vaccines.
    Panatto D; Amicizia D; Lai PL; Gasparini R
    Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.
    Hogea C; Van Effelterre T; Vyse A
    Hum Vaccin Immunother; 2016; 12(2):451-66. PubMed ID: 26308796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
    Zlotnick GW; Jones TR; Liberator P; Hao L; Harris S; McNeil LK; Zhu D; Perez J; Eiden J; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2015; 11(1):5-13. PubMed ID: 25483509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness.
    Poolman JT; Richmond P
    Expert Rev Vaccines; 2015; 14(9):1277-87. PubMed ID: 26204792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances towards the prevention of meningococcal B disease: a multidimensional story.
    Roderick M; Finn A
    J Infect; 2014 Jan; 68 Suppl 1():S76-82. PubMed ID: 24139188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal serogroup B infections: a search for a broadly protective vaccine.
    Vermont CL; van den Dobbelsteen GP
    Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
    Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
    Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serogroup B meningococcal vaccines-an unfinished story.
    Sadarangani M; Pollard AJ
    Lancet Infect Dis; 2010 Feb; 10(2):112-24. PubMed ID: 20113980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.
    Whelan J; Bambini S; Biolchi A; Brunelli B; Robert-Du Ry van Beest Holle M
    Expert Rev Vaccines; 2015 May; 14(5):713-36. PubMed ID: 25603916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].
    Abad R; Martinón-Torres F; Santolaya ME; Banzhoff A; González-Inchausti C; Graña MG; Vázquez JA
    Rev Esp Quimioter; 2019 Jun; 32(3):208-216. PubMed ID: 31148440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Active immunization against serogroup B Neisseria meningitidis].
    Navarro-Alonso JA
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):513-9. PubMed ID: 14572386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.